November 4, 2024 - We’ve introduced a faster and easier way for manufacturers to submit price change requests for generic drugs.
pan-Canadian Pharmaceutical Alliance
Conducting collective expert-informed negotiations for drugs.
What's new at the pCPA
July 10, 2024 - We are pleased to announce Robert Shaffer, assistant deputy minister at the Department of Health in Manitoba, has assumed the role of chair of the Board for the pCPA. Pam Barnes, director of Drug Programs and Services for the Government of Newfoundland and Labrador, is stepping into the role of vice-chair.
The pan-Canadian Pharmaceutical Alliance (pCPA) is an independent organization whose membership includes the provincial, territorial and federal governments. Member jurisdictions collaborate on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments.
One of the pCPA’s key roles is to conduct joint negotiations for brand name and generic drugs in Canada in order to achieve greater value for publicly funded drug programs and patients through its combined negotiating power. Its objectives are to:
- Increase access to clinically relevant and cost-effective treatments
- Achieve consistent and lower drug costs
- Improve consistency in funding decisions
- Reduce duplication and optimize resource utilization
Member jurisdictions
The pCPA member jurisdictions include public drug plans from:
